Mesothelioma
Mesothelioma - Related Videos
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
0 Views •
2022
The goal of this method paper is to demonstrate a robust and reproducible methodology for the enrichment, generation, and expansion of primary tumor cell lines from surgically resected pleural mesothelioma.
11:11
Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells
0 Views •
Cited by 6 •
2018
Desthiobiotin labeling of a synthetic 25-nucleotide RNA oligo, which contains an adenine-rich element (ARE) motif, allows specific binding of cytosolic ARE-binding protein.
09:31
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
0 Views •
Cited by 2 •
2015
The generation of an orthotopic rat model of pleural malignant mesothelioma by implantation of II-45 mesothelioma cells into the pleural cavity of immune competent rats is presented. A flow cytometric method to analyze seven immune cell subsets in these animals from a 25 µl blood sample is also described.
07:54
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
0 Views •
2019
This article describes the generation of an orthotopic mouse model of human pleural mesothelioma by implantation of H2052/484 mesothelioma cells into the pleural cavity of immunocompromised athymic mice. The longitudinal monitoring of the development of intrapleural tumors was assessed by non-invasive multimodal [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography imaging.
FAQs
Asbestos fibers can become lodged in pleural tissue after inhalation. Persistent irritation and inflammation may then contribute to genetic damage, allowing abnormal cells to survive or multiply and form tumors. This mechanism helps explain why the disease can emerge long after exposure rather than immediately. An exposure history provides important clinical context but does not establish a diagnosis by itself.
Mesothelioma may have a long latency period between asbestos exposure and detectable disease. During this interval, persistent irritation and inflammation in pleural tissue can contribute to genetic damage and abnormal cell growth. The extended delay complicates clinical assessment because the relevant exposure may have occurred years earlier, making a detailed exposure history especially important.
Mesothelioma requires a combined evaluation because no single assessment described in the source is sufficient to distinguish it from other cancers. Clinicians consider exposure history, imaging findings, fluid analysis, and tissue biopsy. Using these sources together supports a more informed clinical distinction and helps relate observed disease to the patient's clinical and exposure context.
A clinical workup incorporates the patient's exposure history, imaging, fluid analysis, and tissue biopsy. Each component contributes different information to the overall assessment, while the combination helps clinicians distinguish mesothelioma from other cancers. This integrated approach is important because the diagnosis depends on correlating clinical history with findings from imaging, fluids, and tissue.
Treatment planning depends on disease stage and the patient's overall health. These factors help clinicians determine whether surgery, chemotherapy, radiation, immunotherapy, or combinations are appropriate. Tailoring care in this way recognizes that the same treatment plan may not suit every patient and connects therapeutic choices to the individual's clinical circumstances.
Available approaches include surgery, chemotherapy, radiation, immunotherapy, or combinations of these strategies. The source does not identify one universal regimen; instead, it emphasizes adapting treatment to disease stage and patient health. This range gives clinical teams several therapeutic options to consider when developing an individualized plan for managing the disease.
Research on mesothelioma focuses on earlier detection and more effective targeted therapies. Earlier detection is intended to identify disease sooner, while targeted treatment research seeks therapies that act more effectively against the cancer. These priorities address limitations in current clinical care and guide efforts to improve future diagnosis and treatment.